Search
17 articles for “monoclonal antibody”
-
Monoclonal Antibodies in Next Generation Animal Nutrition: Mapping Nutrient Immune Interaction Networks in Livestock Systems
Abstract: Sustainable livestock production is increasingly constrained by disease pressure, antimicrobial resistance, and declining feed efficiency under intensifying environmental stressors. Conventional nutritional strategies, while essential, remain insufficient to precisely regulate immune function and metabolic resilience. This review explores the emerging role of Monoclonal antibodies as advanced biologics in next generation animal nutrition, with a focus on mapping nutrient immune interaction networks in livestock systems. It synthesizes current knowledge on how nutrients …
Published in International Journal of Molecular Biotechnological Research · Vol. 4, Issue 1, 2026 Read article
-
Monoclonal antibodies in targeted cancer therapy advances, resistance mechanisms, and next-gen formats (Bispesifics, ADCs)
Abstract: Breast cancer is one of the leading causes of cancer-related morbidity and death worldwide, which emphasizes the need for more effective and focused treatment strategies. antibody-mediated drug delivery techniques. Specifically, antibody–drug conjugates (ADCs) have emerged as a potential approach that combines the specificity of monoclonal antibodies with the potent cytotoxicity of anticancer drugs. By selectively targeting tumor-associated antigens, ADCs enhance drug accumulation within cancer cells while minimizing systemic toxicity associated …
Published in Research and Reviews: A Journal of Pharmaceutical Science · Vol. 17, Issue 2, 2026 Read article
-
Engineering Anti-Tau Monoclonal Antibodies for Alzheimer’s Disease and Parkinsonian Tauopathies: A Biotechnological Perspective
Abstract: Neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease are characterized by progressive neuronal loss associated with abnormal protein aggregation. Among these, tauopathies are defined by the accumulation of hyperphosphorylated tau protein, which plays a central role in disease progression. Advances in biotechnology have enabled the development of anti-tau monoclonal antibodies (mAbs) as promising therapeutic agents aimed at neutralizing pathological tau species and inhibiting their propagation. This review provides a …
Published in Research and Reviews : A Journal of Biotechnology · Vol. 16, Issue 1, 2026 Read article
-
Integrative Structural-Functional Genomics of Fc and Fab: Precision Models for Monoclonal Antibody Stability and Anti-Aggregation Engineering
Abstract: Monoclonal antibodies (mAbs) represent the cornerstone of biotherapeutics, yet aggregation propensity compromises up to 50% of candidates during development, driven by Fab hypervariability and Fc vulnerabilities.(1,2) This review integrates functional genomics from OAS (4B+ sequences)(5) and structural databases (SAbDab: 10K+ structures)(6) with machine learning models achieving R=0.97 for SAP prediction.(11) We dissect biophysical mechanisms, benchmark predictive tools (DeepSP, ESM2), and engineering strategies (YTE, FW mutations) that enhance Tm by 5-10°C …
Published in International Journal of Molecular Biotechnological Research · Vol. 4, Issue 1, 2026 Read article
-
Metagenome-Informed Engineering of Monoclonal Antibodies: Mining Microbial Immunoglobulin-Like Domains for Ultra-Stable Therapeutics
Abstract: Metagenome-informed engineering represents an emerging strategy for improving the stability and functionality of monoclonal antibodies (mAbs) by leveraging the vast diversity of microbial immunoglobulin-like (Ig-like) domains (10,24). These domains, derived from uncultured bacteria and bacteriophages, exhibit exceptional thermostability, protease resistance, and structural resilience due to adaptation to extreme environments (29,30). This review highlights advances in metagenomic mining, structural characterization, and protein engineering that enable the integration of microbial Ig-like scaffolds …
Published in Research and Reviews : A Journal of Biotechnology · Vol. 16, Issue 1, 2026 Read article
-
Kisunla (Donanemab): A Novel Breakthrough Illuminating a Path to Better Alzheimer’s Outcomes
Abstract: Background: Alzheimer’s disease (AD) is a progressive neurodegenerative condition marked by cognitive decline, memory loss, and loss of independence. Despite decades of extensive research, disease-modifying treatments have been limited in success. Recent therapeutic advancements have led to the development of monoclonal antibodies targeting amyloid-beta (Aβ) plaques, particularly the pyroglutamate-modified variant, a key pathological hallmark of AD. Objectives: This review aims to explore the therapeutic potential of Donanemab (Kisunla), a novel …
Published in Research and Reviews: A Journal of Neuroscience · Vol. 15, Issue 3, 2025 · pp. 37–45 Read article
-
Advancing Public Health Through Vaccination: A Narrative Review of Respiratory Syncytial Virus (RSV) Immunization Strategies
Abstract: RSV is a significant factor in causing lower respiratory tract infections in children, especially among infants and toddlers. Different age groups are affected by RSV in distinct ways, specifically affecting young children and elderly. People who are immunocompromised are more susceptible to RSV. Centres for Disease Control and Prevention has recommended vaccination doses with the age group to prevent mortality associated with RSV. Signs and symptoms often resemble common cold …
Published in Research and Reviews : A Journal of Immunology · Vol. 14, Issue 1, 2024 · pp. 1–6 Read article
-
Strategy to Accelerate the Biopharmaceuticals Production Using Komogataella phaffii (Pichia pastoris)
Abstract: Revenue generation has been the primary goals for nations as well as the industries worldwide. Biopharmaceutical verticals have become potential revenue generators as they are the industrial workhorses and the economic engines that drive the upcoming biopharmaceutical industries with advances in DNA recombinant technology. A breakthrough in the indusrial biotechnology for the production of biopharmaceuticals using Pichia pastoris is awaited. Ablynx NV, Recombinant proteins (RP), HSA-pFSH beta, antibodies, borosin, N-glycoprotein, …
Published in International Journal of Advance in Molecular Engineering · Vol. 2, Issue 2, 2024 · pp. 1–7 Read article
-
Impact of Therapeutics on Carbapenem-Resistant Acinetobacter baumannii
Abstract: Acinetobacter baumannii, a formidable pathogen in healthcare settings, poses a significant threat due to its propensity to cause nosocomial infections. This bacterium exhibits several attributes that enable it to evade the human body's natural defenses. A. baumannii's remarkable adaptability is highlighted by its ease in acquiring antibiotic resistance determinants, rendering it challenging to treat. Its ability to thrive in hospital environments underscores the urgent need for stringent infection control practices …
Published in Research and Reviews: A Journal of Microbiology and Virology · Vol. 14, Issue 2, 2024 · pp. 1–11 Read article
-
Current Drugs Target the EGFR
Abstract: Cancer is a devastating disease, but there have recently been significant advancements in therapy that have identified EGFR and its related proteins as valuable indicators and targets for treatment. The ERBB receptor tyrosine kinase superfamily includes EGFR, which is a transmembrane glycoprotein. When the EGFR receptor interacts to its particular ligand, EGF, it causes tyrosine residues to be phosphorylated and forms receptor dimers with other members of the receptor family. …
Published in Research and Reviews : A Journal of Medical Science and Technology · Vol. 13, Issue 2, 2024 · pp. 1–8 Read article
-
Immunotherapy Advancements in Cancer Treatment
Abstract: Immuno-oncology has been one of the more exciting developments in the field of cancer treatment since about a century ago, with William B. Coley's work in the late 19th century, which really gave the field its beginnings with "Coley's toxin." In an initial effort that proved unsuccessful, early immunotherapy approaches utilizing bacterial mixtures to induce immune responses against tumors nonetheless laid some groundwork for this field. It wasn't until over …
Published in Research and Reviews: A Journal of Pharmacology · Vol. 14, Issue 3, 2024 · pp. 22–28 Read article
-
Breakthroughs in Biotechnology for the Regulation of Infectious Diseases
Abstract: Infectious diseases have a heavy impact on both public health and the world’s economies. In most diseases, antibiotic resistance has become widespread over time. A variety of diseases comprising pneumonia, tuberculosis, and gonorrhea go through the same evolutionary processes, which include the formation of drug-resistant pathogens in response to selection pressure from medications and their potential extinction when drug use is ceased. Since the occurrence of drug resistance in serious …
Published in Research and Reviews : A Journal of Biotechnology · Vol. 15, Issue 1, 2025 · pp. 1–25 Read article
-
Emerging Therapies in Respiratory Tract Infections: Current Advances and Future Perspectives
Abstract: The impact of respiratory tract infections (RTI) as a global public health problem continues to be high morbidity and mortality rates. The development of novel therapeutic approaches stemmed from the fact that conventional treatment strategies, antibiotics, antivirals, antifungals etc. have become increasingly ineffective because of rise of antimicrobial resistance (AMR). Next generation therapies, such as novel antimicrobial agents, host directed therapies and novel drug delivery systems have come on the …
Published in Recent Trends in Infectious Diseases · Vol. 2, Issue 2, 2025 · pp. 17–25 Read article
-
Revolutionizing Blood Cancer Treatment: Emerging Therapies and Future Perspectives
Abstract: Blood cancer inclusive of leukemia, lymphoma and multiple myeloma poses a significant threat in the world today because of its multifactorial process and its non-amenable to standard therapies. Some of such approaches are immunotherapy, gene-editing technology and targeted small molecule inhibitors that have altered the nature of treatments. CAR T cell therapy is a molecular targeted therapy for cancers and several clinical studies have reported a huge success. Also, the …
Published in International Journal of Biomedical Innovations and Engineering · Vol. 3, Issue 2, 2025 Read article
-
Drug Resistance in Targeted Cancer Treatment: Clinical Difficulties, Molecular Mechanisms, and Emerging Strategies
Abstract: Targeted cancer therapy, which selectively inhibits the molecular mechanisms responsible for tumor growth and development, has revolutionized modern oncology. Targeted therapies have lower systemic toxicity and better therapeutic efficacy when compared to traditional chemotherapy. However, the emergence of medication resistance often limits the long-term efficacy of these treatments, ultimately resulting in treatment failure and disease progression. Drug resistance develops through a number of intricate biological processes and can be innate …
Published in Research and Reviews: A Journal of Pharmaceutical Science · Vol. 17, Issue 1, 2026 · pp. 130–138 Read article
-
Strategies for the Development and Optimization of Orally Disintegrating Tablets (ODTs) to Improve Bioavailability and Patient Compliance
Abstract: Background: Pharmaceutical scientists have developed Orally Disintegrating Tablets (ODTs) to advance patient drug acceptance and biological system availability through simplified medi-cation delivery especially for children and senior citizens and people who cannot swallow pills regularly. The oral disintegrating tablets dissolve in the mouth within thirty seconds or less (USP 701) while needing no additional liquid thus making them suitable for both emergency treatments. Objective: The research examines ODT development strategies …
Published in Research & Reviews: A Journal of Drug Design & Discovery · Vol. 13, Issue 2, 2026 Read article
-
Toxicological Profiling and Safety Assessment of NASAT 2.0: A Conceptual Framework for Adaptive Nanoparticle Therapy in Rabies
Abstract: Rabies, caused by the highly neurotropic Rabies lyssavirus, remains one of the most enigmatic and universally lethal infectious diseases known to modern medicine. Once clinical symptoms manifest following successful neuroinvasion, the fatality rate approaches absolute certainty (approximately 99.9%), a staggering statistic that has remained largely unchallenged despite massive, concurrent advances in modern virology, critical care medicine, and cellular immunology. Current late-stage therapeutic protocols, most notably the widely debated Milwaukee Protocol, …
Published in Research and Reviews: A Journal of Toxicology · Vol. 16, Issue 2, 2026 · pp. 1–19 Read article